Cevira delivers a light-activated treatment known as photodynamic therapy to destroy tissue infections caused by HPV and treat precancerous lesions on the cervix without affecting healthy tissue.
Cevira contains a LED light source in combination with a drug that initiates a photochemical reaction in exposed tissue.
The device can be administered by a trained gynaecologist or colposcopist and is left in the cervix up to one-day, during which time the patient can leave the hospital and continue with her daily activities, allowing the patient remove and dispose the device herself.
The trials will evaluate the photodynamic therapy in patients with cervical pre-cancer as an alternative to laser therapy, surgical conisation, LEEP excision or cryotherapy and investigate treatment suitability in patients with mild cervical abnormalities.